Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Clear all
Withdrawn No phase listed Observational

Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI)

NCT01083355
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Results available

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

NCT01775774
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Not applicable Interventional Results available

Airway Pressure Release Ventilation in Acute Lung Injury

NCT00750204
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
Interventions
APRV, Conventional MV
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

NCT02549222
View directory record Official record
Conditions
Transfusion Related Acute Lung Injury
Interventions
Standard of Care
Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
2,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

Lung Injury Prediction Study

NCT00889772
View directory record Official record
Conditions
Respiratory Distress, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 3 Interventional

Calfactant for Direct Acute Respiratory Distress Syndrome

NCT00682500
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Calfactant, Room Air (placebo)
Drug
Lead sponsor
Pneuma Pharmaceuticals Incorporated
Other
Eligibility
12 Years to 85 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Gainesville, Florida • Orlando, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Jul 21, 2026, 11:12 AM EDT
Not yet recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
View directory record Official record
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jul 21, 2026, 11:12 AM EDT
Not yet recruiting Not applicable Interventional

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

NCT07634419
View directory record Official record
Conditions
Critical Illness, Heart Failure, Sepsis, Ards, Pneumonia, Trauma Injury
Interventions
Lift mobile mindfulness, Enlighten Recovery education program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Early Insulin and Development of ARDS

NCT00605696
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06701682
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

Severe ARDS: Generating Evidence

NCT03021824
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Trial of Therapeutic Hypothermia in Patients With ARDS

NCT04545424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 3 Interventional

Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)

NCT00883948
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
39
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

TD-0903 for ALI Associated With COVID-19

NCT04402866
View directory record Official record
Conditions
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Interventions
TD-0903, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Duarte, California • Denver, Colorado • Sebring, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 2Phase 3 Interventional

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096
View directory record Official record
Conditions
SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo
Drug · Device
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jul 21, 2026, 11:12 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Post-Hospital Case Management to Improve Clinical Outcomes in Individuals Requiring Mechanical Ventilation

NCT00149513
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Targeted Case Management, Usual care
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971
View directory record Official record
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)

NCT03654352
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Sturgill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease

NCT00217880
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Bronchoscopy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

NCT01597635
View directory record Official record
Conditions
Lung Injury, Acute
Interventions
Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881, Dose 4 GSK2586881, Placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sacramento, California • Chicago, Illinois • Springfield, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Jul 21, 2026, 11:12 AM EDT